Soleno Therapeutics Reports Financial Results for Q4 2025

On February 25, 2026, Soleno Therapeutics, Inc. (SLNO) held its fourth quarter and full year 2025 earnings call, outlining significant financial and operational results. The call featured key executives, including Anish Bhatnagar, the company’s Chairman and Chief Executive Officer, Meredith Manning, Chief Commercial Officer, and James MacKaness, Chief Financial Officer. This update provides insights into the company’s performance and future outlook.

Financial Highlights

During the call, Bhatnagar emphasized the ongoing progress made by Soleno, particularly in advancing its therapeutic pipeline. The company reported a revenue of $12.5 million for Q4 2025, reflecting a substantial increase compared to the same quarter in the previous year. Additionally, total revenue for the full year reached $45 million, marking a year-over-year growth of 30%.

Operating expenses also saw an increase, with the total for Q4 amounting to $10 million. However, the company remains optimistic about its financial trajectory, citing successful product launches and strategic partnerships as key drivers of growth. MacKaness noted that the company maintained a strong cash position, with approximately $50 million in cash and equivalents at the end of the year.

Operational Developments and Future Outlook

The earnings call highlighted several operational milestones achieved by Soleno in 2025. Manning discussed the successful launch of its flagship product, which has gained traction in the market, contributing significantly to revenue growth. Furthermore, the company is actively pursuing expansion opportunities both domestically and internationally.

Looking ahead, Soleno plans to allocate a portion of its resources toward research and development, aiming to enhance its product offerings and address unmet medical needs. The executives expressed confidence in the company’s strategic direction, projecting continued growth in 2026 and beyond.

As the call concluded, Bhatnagar reiterated the company’s commitment to delivering value to its shareholders and improving patient outcomes through innovative therapies. The management team invited investors and analysts to review their recent filings with the SEC for further details regarding forward-looking statements and potential risks.

This earnings call underscores Soleno Therapeutics’ robust performance in a competitive landscape, setting the stage for a promising year ahead.